NCT07004244 - Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Malignant Tumors

Interventions

BIOLOGICAL

KRAS-mutated mRNA vaccine

"Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose.~Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery"

BIOLOGICAL

TORIPALIMAB

intravenous injection

DRUG

Pemetrexed+carboplatin

intravenous injection

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

collaborator

West China Hospital

OTHER

lead

Sichuan University

OTHER